Aastrom Biosciences ends drug trial, to cut half its workforce

March 27 Wed Mar 27, 2013 9:06am EDT

March 27 (Reuters) - Aastrom Biosciences Inc said it would end the late-stage trial of its drug to treat critical limb ischemia - a form of peripheral arterial disease - and cut about half of its workforce.

The company now plans to focus on its experimental treatment for a heart condition called dilated cardiomyopathy, in which the heart becomes weak and cannot pump blood efficiently.

The company has about 71 employees, according to Thomson Reuters data.